B cells in classical Hodgkin lymphoma are important actors rather than bystanders in the local immune reaction.

[1]  Y. Richard,et al.  Revisiting the B-cell compartment in mouse and humans: more than one B-cell subset exists in the marginal zone and beyond , 2012, BMC Immunology.

[2]  T. Habermann,et al.  Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. , 2012, Blood.

[3]  A. Liston,et al.  T‐follicular helper cell differentiation and the co‐option of this pathway by non‐helper cells , 2012, Immunological reviews.

[4]  R. Hassan,et al.  Disease patterns in pediatric classical Hodgkin lymphoma: a report from a developing area in Brazil , 2011, Hematological oncology.

[5]  E. Morii,et al.  Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma , 2011, Virchows Archiv.

[6]  A. Cunningham,et al.  B cell priming for extrafollicular antibody responses requires Bcl-6 expression by T cells , 2011, The Journal of experimental medicine.

[7]  G. Grabenbauer,et al.  Inflammation in gastric adenocarcinoma of the cardia: how do EBV infection, Her2 amplification and cancer progression influence tumor-infiltrating lymphocytes? , 2011, Virchows Archiv.

[8]  B. Nelson,et al.  CD20+ B Cells: The Other Tumor-Infiltrating Lymphocytes , 2010, The Journal of Immunology.

[9]  A. Carbone,et al.  The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape , 2010, The Journal of pathology.

[10]  Steven J. M. Jones,et al.  Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. , 2010, The New England journal of medicine.

[11]  M. Siedner,et al.  Circulating clonotypic B cells in classic Hodgkin lymphoma. , 2009, Blood.

[12]  L. Staudt,et al.  IRF4: Immunity. Malignancy! Therapy? , 2009, Clinical Cancer Research.

[13]  T. Molina,et al.  Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. , 2009, Blood.

[14]  G. Grabenbauer,et al.  Prognostic impact of tumour‐infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma , 2009, Hematological oncology.

[15]  H. Kölbl,et al.  The humoral immune system has a key prognostic impact in node-negative breast cancer. , 2008, Cancer research.

[16]  H. Tilly,et al.  Transitional B cells in humans: characterization and insight from B lymphocyte reconstitution after hematopoietic stem cell transplantation. , 2008, Clinical immunology.

[17]  I. Sanz,et al.  Phenotypic and functional heterogeneity of human memory B cells. , 2008, Seminars in immunology.

[18]  Stefano A Pileri,et al.  Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin’s lymphoma , 2008, Haematologica.

[19]  A. Anastasi,et al.  Tumor-infiltrating B lymphocytes as an efficient source of highly specific immunoglobulins recognizing tumor cells , 2007, BMC biotechnology.

[20]  K. Fink,et al.  CD38 cross‐linking enhances TLR‐induced B cell proliferation but decreases IgM plasma cell differentiation , 2007, European journal of immunology.

[21]  Sergey W. Popov,et al.  AID expression identifies interfollicular large B cells as putative precursors of mature B-cell malignancies. , 2006, Blood.

[22]  B. Jungnickel,et al.  Differential expression of activation‐induced cytidine deaminase (AID) in nodular lymphocyte‐predominant and classical Hodgkin lymphoma , 2005, The Journal of pathology.

[23]  Giovanna Roncador,et al.  Outcome in Hodgkin's Lymphoma Can Be Predicted from the Presence of Accompanying Cytotoxic and Regulatory T Cells , 2005, Clinical Cancer Research.

[24]  W. Fridman,et al.  Immunoglobulin repertoire of B lymphocytes infiltrating breast medullary carcinoma. , 2004, Human antibodies.

[25]  J. Delfraissy,et al.  In human B cells, IL-12 triggers a cascade of molecular events similar to Th1 commitment. , 2003, Blood.

[26]  S. Pileri,et al.  Phenotype and genotype of interfollicular large B cells, a subpopulation of lymphocytes often with dendritic morphology. , 2003, Blood.

[27]  P. Mclaughlin,et al.  A pilot study of rituximab in patients with recurrent, classic Hodgkin disease , 2003, Cancer.

[28]  G. Bonadonna,et al.  CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  A. van den Berg,et al.  High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. , 1999, The American journal of pathology.

[30]  A. Baur,et al.  Prognostic value of follicular dendritic cells in nodular sclerosing Hodgkin's disease , 1998, Histopathology.

[31]  C. Lautenschläger,et al.  Phenotypic analysis of T lymphocytes isolated from non-small-cell lung cancer. , 1997, International archives of allergy and immunology.

[32]  C. Fellbaum,et al.  Follicular dendritic cells have prognostic relevance in Hodgkin's disease. , 1994, American journal of clinical pathology.

[33]  R. Bataille,et al.  The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. , 2006, Haematologica.

[34]  M. Andreeff,et al.  Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease , 2002, Cancer.

[35]  H. Herbst,et al.  In situ detection of Epstein-Barr virus DNA and viral gene products. , 2001, Methods in molecular biology.